The new conjugate vaccine MCV4 promises longer duration of immunity and, perhaps, greater clinical efficacy than the polysaccharide vaccine MPSV4. Questions remain about booster doses, vaccinating young children, and safety.
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.